Linda H. Malkas, Ph.D. Research

Active:
"caPep:evaluation of an agent that targets MYCN-amplified neuroblastoma." Role: Principal Investigator. Total Cost $ 100,000.
  • Department of Defense Medical Research and Development Command Breast Cancer Research Program (2010-2013)
  • “Peptides Directed Against Cancer Associated PCNA Has Therapeutic Potential in Breast Cancer”.  Role: Principal Investigator
  • Department of Defense Medical Research and Development Command Research Program (2011-2014)
  • New Molecular Target for Neuroblastoma Therapy.  The goal of this project is to evaluate the isoform of proliferating cell nuclear antigen (caPCNA), expressed by cancer cells and tumor tissue, as a potential therapeutic target for the treatment of neuroblastoma. Role: Principal Investigator
  • NIH/NCI Cancer Center Support Grant  [Friedman (PI)]  (2012-2017)
  • This project supports the research programs that have been established to allow successful collaboration among basic and clinical researchers. Roles: Deputy Director for Basic Research and Co-Leader--Molecular Oncology Program
  • St. Baldrick’s Foundation (2013-2014)
  • National Institutes of Health/National Cancer Institute Public Health Service Award (2007-2014)
  • "A Structure/function analysis of a tumor specific protein (R01)" The goal of this project is to show that the unique structure and function of an isoform of proliferating cell nuclear antigen (caPCNA), expressed by breast cancer cells and tumor tissue, plays an important role in the proliferation and progression of these cancer cells.
 
Completed:
  • Indiana University Purdue University Indianapolis Signature Center Award (2010-2013)
  • The Indiana Signature Center for Breast Cancer Research.  The spectrum of studies to be performed includes the development of novel agents, technologies, and markers for the better diagnosis, prognosis, screening, prevention, and treatment of breast cancer.  Role: Director/Principal Investigator - signed award over to another PI upon leaving Indiana University
  • DOD Center of Excellence (BC030400)  [Sledge (PI)]  (2004-2011)
  • “Center of Excellence for Individualization of Therapy for Breast Cancer” The purpose of the Center of Excellence was to combine the emerging technologies of genomics, proteomics, and pharmacogenetics / pharmacogenomics to predict the response to commonly used chemotherapeutic agents and novel targeted agents in the setting of advanced breast cancer.  The predicted outcome of such analyses was therapeutic individualization (the matching of individual agents to specific patients most likely to benefit in the least toxic possible manner).  Role: Co-Leader